These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 7962341

  • 1. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 3. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.
    Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, Mucci M, Boghen MF, Camanni F.
    J Endocrinol Invest; 1994 Mar; 17(3):157-62. PubMed ID: 8051337
    [Abstract] [Full Text] [Related]

  • 4. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.
    Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F.
    J Clin Endocrinol Metab; 1994 Mar; 78(3):693-8. PubMed ID: 8126144
    [Abstract] [Full Text] [Related]

  • 5. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [Abstract] [Full Text] [Related]

  • 6. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E.
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [Abstract] [Full Text] [Related]

  • 7. Modulation of growth hormone-releasing activity of hexarelin in man.
    Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498
    [Abstract] [Full Text] [Related]

  • 8. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [Abstract] [Full Text] [Related]

  • 9. Effect of 15-day treatment with growth-hormone-releasing hormone alone or combined with different doses of arginine on the reduced somatotrope responsiveness to the neurohormone in normal aging.
    Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Muller EE, Camanni F.
    Eur J Endocrinol; 1995 Jan; 132(1):32-6. PubMed ID: 7850007
    [Abstract] [Full Text] [Related]

  • 10. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E, Maccagno B, Ramunni J, Gianotti L, Di Vito L, Deghenghi R, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [Abstract] [Full Text] [Related]

  • 11. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.
    Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Cocchi D, Müller EE, Camanni F.
    J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330
    [Abstract] [Full Text] [Related]

  • 12. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.
    Maccario M, Arvat E, Procopio M, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159
    [Abstract] [Full Text] [Related]

  • 13. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R, Valente F, Dieguez C, Zini M, Procopio M, Portioli I, Ghigo E.
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [Abstract] [Full Text] [Related]

  • 14. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF, Hindmarsh PC, Brook CG.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [Abstract] [Full Text] [Related]

  • 15. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G, Grugni G, Morabito F.
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [Abstract] [Full Text] [Related]

  • 16. The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.
    Bartolotta E, Bellone J, Aimaretti G, Arvat E, Benso L, Deghenghi R, Camanni F, Ghigo E.
    J Pediatr Endocrinol Metab; 1997 Dec; 10(5):491-7. PubMed ID: 9401905
    [Abstract] [Full Text] [Related]

  • 17. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [Abstract] [Full Text] [Related]

  • 18. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, Müller EE.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [Abstract] [Full Text] [Related]

  • 19. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 20. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG, Macfarlane P, Levitt NS, Millar RP.
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.